AngelEye Health, a provider of neonatal and paediatric family engagement services, has agreed to acquire the Early Detection Neuromotor Assessments (EDNA) portfolio from Enlighten Mobility.
Financial terms and other details of the transaction remain undisclosed.
The strategic move aims to bolster AngelEye’s capabilities in utilising bedside sensors for early intervention in neonatal care.
The integration of the EDNA platform into AngelEye, utilised across nearly 250 hospitals and more than 7,000 bedsides, is expected to make a significant impact on neonatal intensive care unit (NICU) care.
The EDNA platform employs movement analysis, clinical expertise, sensors, and artificial intelligence to identify risk factors in newborns, such as neuromotor issues, positioning, or sepsis.
These risks can often lead to extended hospital stays and long-term health complications.
EDNA's sensor-based platform provides clinicians with vital information, enabling them to support infants and their families more effectively from an early stage, thereby improving outcomes.
The algorithms and clinical service model of EDNA have been developed in collaboration with top scientists and hospitals, including Nationwide Children’s Hospital.
Research is ongoing to further validate and discover additional sensor-based algorithms and services for newborns, AngelEye said.
AngelEye Health CEO Christopher Rand said: “The acquisition of the EDNA portfolio is a pivotal moment for AngelEye.
“By combining our industry-leading footprint with EDNA’s portfolio, we gain the ability to extend our reach beyond engagement and into the realm of supporting clinical care.
“This strategic transaction enables us to use our established relationships and infrastructure in the NICU to provide clinicians a greater capability to identify at-risk patients, and support their care journey in the NICU and beyond.”
The latest acquisition further marks a significant step for AngelEye Health in its mission to enhance neonatal care, extending its reach from family engagement to direct clinical support.
Since its inception in 2013, AngelEye said it has maintained a high retention rate of over 98% and has formed partnerships with hospitals across the US, the EU, Canada, and Australia.
